[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diffuse-midline-glioma-h3-k27-altered\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diffuse-midline-glioma-h3-k27-altered":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100610088","phase-1-a-study-of-177lu-psma-617-in-people-with-gliomas-100610088",false,"NCT07223034","A Study of 177Lu-PSMA-617 in People With Gliomas","LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment","Inclusion Criteria:\n\n* Confirmed histologic diagnosis of a WHO grade 2-4 glioma that is IDH1 R132H-wildtype, including the following:\n\n  * Diffuse astrocytoma, IDH-wildtype (grade 2-4)\n  * Glioblastoma, IDH-wildtype\n  * Diffuse midline glioma, H3 K27-altered\n  * Diffuse hemispheric glioma, H3 G34-mutant\n  * Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype PSMA positive pathological stain (by immunohistochemistry) of baseline (pre-radiotherapy) resection or biopsy sample\n* Completion of standard of care therapy including surgery (for resectable tumors) and adjuvant EBRT for glioma\n* Patients must be on a dose of 4 mg or less of dexamethasone (or dexamethasone equivalent steroid) for 5 days prior to first planned dose of radiopharmaceutical\n* Age ≥ 18\n* ECOG ≤ 2\n* Serum creatinine level \\\u003C 1.5 x ULN or EGFR \\> 60 mL\u002Fmin\n* Liver laboratory values: ALT and AST ≤ 2.5 x ULN; Albumin \\> 2 g\u002F dL; Bilirubin \\\u003C 3 X ULN\n* Normal organ and marrow function as defined as the following\n\n  * Total white blood count \\> 3.0 K\u002FmcL\n  * ANC ≥ 1.5 K\u002FmcL\n  * Platelets ≥ 100 K\u002FmcL\n  * Hemoglobin ≥ 9 g\u002FdL\n* Adequate contraception prior to registration (see section 9.0)\n* Ability to understand, and willingness to sign the informed consent.\n\nExclusion Criteria:\n\n* Patient known to harbor any other non-canonical IDH mutations (i.e., non-R132H)\n* Target lesion within 5 mm of either the brainstem, optic chiasm or optic nerves Receipt of bevacizumab as part of the initial treatment for glioma\n* Life expectancy less than 12 weeks\n* Nonhealing wound, ulcer or bone fracture\n* History of severe brain injury\n* Patient not eligible for sequential MRI evaluations\n* Patients with prior RT to \\> 25% of the skeleton or prior exposure to prior Radium223, Strontium89 or Samarium153 containing compounds\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Unable to tolerate the PSMA PET\u002FMR or PSMA PET\u002FCT\n* History of viral hepatitis or chronic liver disease with active symptoms\n* History of pituitary or adrenal dysfunction\n* Previously diagnosed active infection (e.g., human immunodeficiency virus \\[HIV\\] or viral hepatitis)\n* Any condition that in the opinion of the investigator, would preclude participation in this study\n* Receipt of any other investigational agents or participation in a concurrent treatment protocol\n* Known allergies, hypersensitivities, or intolerance to 68Ga-PSMA-11\u002F177Lu-PSMA-617 or its inactive compounding components\n* Current or planned pregnancy\n* Refusal to comply with detailed contraception requirements","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.",[26,27,28,29,30,31],"Glioma","Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)","Glioblastoma, IDH-wildtype","Diffuse Midline Glioma, H3 K27-Altered","Diffuse Hemispheric Glioma, H3 G34-mutant","Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-04","ACTUAL",{"date":38,"type":36},"2025-10-27",{"date":40,"type":20},"2027-10",{"name":42,"class":43},"Memorial Sloan Kettering Cancer Center","OTHER",7,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100429351","phase-1-cbl0137-for-the-treatment-of-relapsed-or-refractory-solid-tumors-including-cns-tumors-and-lymphoma-100429351","NCT04870944","CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","A Phase 1\u002F2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma","Inclusion Criteria:\n\n* Parts A and B: Patients must be \\>= 12 months and =\\\u003C 21 years of age at the time of study enrollment\n* Patients must have had histologic verification of malignancy at original diagnosis or relapse, except in patients with diffuse intrinsic brain stem tumors, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers, including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)\n\n  * Part A: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or known CNS metastases (including untreated or progressive) are eligible\n  * Part B: Patients with progressive or recurrent DIPG (diagnosed by biopsy or imaging characteristics) and other H3 K27-altered DMG previously treated with radiation therapy\n* Part A: Patients must have either measurable or evaluable disease\n* Part B: Patients must have measurable disease\n* Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life\n* Patients must have a performance status corresponding to Easter Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \\> 16 years of age and Lansky for patients =\\\u003C 16 years of age. Patients must have a Karnofsky or Lansky score \\>= 50%\n* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately\n\n  * Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive\n\n    * Solid tumor patients: \\>= 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)\n  * Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil count \\[ANC\\] counts): \\>= 7 days after the last dose of agent\n  * Antibodies: \\>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\\\u003C 1\n  * Corticosteroids: If used to modify immune adverse events related to prior therapy, \\>= 14 days must have elapsed since last dose of corticosteroid. Patients with CNS tumors receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment\n  * Hematopoietic growth factors: \\>= 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur\n  * Interleukins, interferons and cytokines (other than hematopoietic growth factors): \\>= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)\n  * Stem cell Infusions (with or without total body irradiation \\[TBI\\]):\n\n    * Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: \\>= 84 days after infusion and no evidence of graft versus host disease (GVHD)\n    * Autologous stem cell infusion including boost infusion: \\>= 30 days\n  * Cellular therapy: \\>= 42 days after the completion of any type of cellular therapy (e.g., modified T cells, natural killer \\[NK\\] cells, dendritic cells, etc.)\n  * Radiation therapy \\[XRT\\]\u002Fexternal beam irradiation including protons: \\>= 14 days after local XRT; \\>= 150 days after TBI, craniospinal XRT or if radiation to \\>= 50% of the pelvis; \\>= 42 days if other substantial bone marrow (BM) radiation\n  * Radiopharmaceutical therapy (e.g., radiolabeled antibody, I-131 metaiodobenzylguanidine \\[131I MIBG\\]): \\>= 42 days after systemically administered radiopharmaceutical therapy\n  * Patients must not have received prior exposure to CBL0137\n* For patients with solid tumors without known bone marrow involvement:\n\n  * Peripheral absolute neutrophil count (ANC) \\>= 1000\u002FuL (performed within 7 days prior to enrollment unless otherwise indicated)\n  * Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions). These patients will not be evaluable for hematologic toxicity. At least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study. If dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity\n* For patients with solid tumors without known bone marrow involvement:\n\n  * Platelet count \\>= 100,000\u002FuL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) (performed within 7 days prior to enrollment unless otherwise indicated)\n  * Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions). These patients will not be evaluable for hematologic toxicity. At least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study. If dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \\>= 70 mL\u002Fmin\u002F1.73 m\\^2 or a creatinine based on age\u002Fsex as follows (performed within 7 days prior to enrollment unless otherwise indicated):\n\n  * Age: Maximum serum creatinine (mg\u002FdL)\n  * 1 to \\\u003C 2 years: 0.6 (male); 0.6 (female)\n  * 2 to \\\u003C 6 years: 0.8 (male); 0.8 (female)\n  * 6 to \\\u003C 10 years: 1 (male); 1 (female)\n  * 10 to \\\u003C 13 years: 1.2 (male); 1.2 (female)\n  * 13 to \\\u003C 16 years: 1.5 (male); 1.4 (female)\n  * \\>= 16 years: 1.7 (male); 1.4 (female)\n* Patients with solid tumors:\n\n  * Bilirubin (sum of conjugated + unconjugated or total) =\\\u003C 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment unless otherwise indicated)\n* Patients with solid tumors:\n\n  * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \\[ALT\\]) =\\\u003C 135 U\u002FL. For the purpose of this study, the ULN for SGPT is 45 U\u002FL (performed within 7 days prior to enrollment unless otherwise indicated)\n* Shortening fraction of \\>= 27% by echocardiogram (performed within 7 days prior to enrollment unless otherwise indicated) or\n* Ejection fraction of \\>= 50% by gated radionuclide study (performed within 7 days prior to enrollment unless otherwise indicated)\n* Corrected QT (QTC) \\\u003C 480 msec (performed within 7 days prior to enrollment unless otherwise indicated)\n* Patients with seizure disorder may be enrolled if seizures well controlled without the use of enzyme-inducing anti-convulsant agents. Well controlled is defined by no increase in seizure frequency in the prior 7 days\n* Nervous system disorders (Common Terminology Criteria for Adverse Events \\[CTCAE\\] version \\[v\\]5) resulting from prior therapy must be =\\\u003C grade 2, with the exception of decreased tendon reflex (DTR). Any grade of DTR is eligible\n* Patients have consented to receive a central venous catheter prior to the administration of CBL0137. A central line is required for CBL0137 administration\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal\u002Fhuman studies, OR because there is yet no available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two effective methods of birth control, including a medically accepted barrier or contraceptive method (e.g., male or female condom) for the duration of the study. Abstinence is an acceptable method of birth control\n* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, \\>= 14 days must have elapsed since last dose of corticosteroid\n* Patients who are currently receiving another investigational drug are not eligible\n* Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)\n* Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\n* Patients who are receiving drugs that are strong inducers or inhibitors of CYP3A4, CYP2B6 (e.g., carbamazepine) and CYP1A2 (e.g., ciprofloxacin, enoxacin, fluvoxamine, smoking) are not eligible. These agents are to be avoided for 7 days prior to the start of CBL0137 and for the duration of the protocol therapy. Sensitive substrates of CYP2D6 (e.g., atomoxetine, desipramine, dextromethorphan, eliglustat, nebivolol, nortriptyline, perphenazine, tolterodine, R-venlafaxine) should also be avoided for the duration protocol therapy\n* Patients who are receiving drugs associated with a known risk of Torsades de Pointes (TdP) are not eligible. Drugs associated with known risk of Torsades de Pointes (TdP) are to be avoided for 7 days prior to the start of CBL0137 and for duration of the protocol therapy\n* Patients with known peripheral vascular disease are excluded\n* Patients with a history of pro-thrombotic disorder are not eligible\n* Patients who have an uncontrolled infection are not eligible\n* Patients who have received a prior solid organ transplantation are not eligible\n* Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible","12 Months","21 Years",{"count":55,"type":20},63,[23,57],"PHASE2","This phase I\u002FII trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.",[29,60,61,62,63,64,65,66,67,68],"Metastatic Malignant Neoplasm in the Central Nervous System","Recurrent Diffuse Intrinsic Pontine Glioma","Recurrent Diffuse Midline Glioma, H3 K27-Altered","Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Primary Malignant Central Nervous System Neoplasm","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Primary Malignant Central Nervous System Neoplasm","2026-05-01",{"date":71,"type":36},"2026-05-05",{"date":73,"type":36},"2022-01-28",{"date":75,"type":20},"2026-12-31",{"name":77,"class":78},"Children's Oncology Group","NETWORK",35,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100636229","phase-1-focused-ultrasound-blood-brain-barrier-opening-in-pontine-diffuse-midline-glioma-to-enhance-temozolomide-therapy-pilot-feasibility-study-fides-100636229","NCT07562971","Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)","Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy With Temozolomide (FIDES) - an Exploratory Pilot and Feasibility Trial","FIDES","Inclusion Criteria:\n\n* Age ≥ 4 years.\n* Histologically\u002Fmolecularly verified de novo pontine H3K27-altered diffuse midline glioma.\n* Main localization ('center of mass') in the brainstem. NB: some degree of extension beyond the brainstem, e.g. cerebellar peduncles, is allowed.\n* Karnofsky Performance Score (KPS) or Lansky Performance Score (LPS) of ≥ 70\u002F KPS or LPS 60 and WHO\u002FECOG performance status ≤ 2.\n* ASA-score of I-III.\n* Intention to treat with (TMZ chemo-) radiation and maintenance TMZ as per consensus of the local multidisciplinary tumor board.\n* Feasible to schedule the first Exablate BBBO procedure preferably within 4-6 weeks, acceptably within 12 weeks, after successful completion of radiotherapy\u002F concomitant TMZ-chemoradiation, defined as completed treatment as planned without reported CTCAEv6.0 grade 3-4 toxicities or, in case of reported CTCAEv6.0 grade 3-4 toxicities, the toxicities must be resolved to grade 2 prior to inclusion.\n* If on steroids, stable or decreasing dose for at least 7 days prior to inclusion.\n* Able to attend all study visits.\n* Able and willing to give informed consent or have a legal guardian who is able and willing to do so.\n\nExclusion Criteria:\n\n* Previous or ongoing participation in other clinical trials with other than standard-of-care tumor-directed treatment(s) for H3K27-altered DMG.\n* Multifocal or leptomeningeal metastasized disease. Multifocal disease is defined as multiple FLAIR-hyperintense lesions, separated by normal-appearing brain tissue, with or without gadolinium enhancement. Multiple enhancing regions within one continuous FLAIR lesion can be considered as unifocal disease.\n* Signs\u002Fsymptoms of elevated intracranial pressure (ICP) (e.g. headache, vomiting, impaired vision\u002Fpapilledema, impaired consciousness), with corresponding radiographic findings on MRI at time of screening.\n* Severe dysphagia with feeding tube dependency.\n* Evidence of acute clinically significant intracranial hemorrhage. NB: minimal hemorrhagic foci without obvious related clinical symptoms will not serve as grounds for exclusion.\n* Tumor not visible on any pre-therapy or post-radiation imaging.\n* Presence of extracranial \u002F intracranial structures (e.g. metal prostheses, implants, calcifications) on pre-treatment CT-scan\u002F MRI-scan, significantly interfering with acoustic impedance as per judgement of the researchers.\n* Known co-occurring other malignancy that is progressing or has required active treatment within the past 3 years, with exception of: carcinomas in situ (CIS) and non-melanoma skin cancers.\n* Patients with right-to-left, bi-directional or transient right-to-left cardiac shunts.\n* Known LVEF \\\u003C 40 or unstable hemodynamics.\n* Severe hypertension, not adequately controlled with study compatible medication (Adults: RR systolic \\>180 and\u002F or RR diastolic \\>100; Children: \\>p95 + 12mmHg).\n* History of bleeding disorder and\u002For coagulopathy.\n* Treatment with anti-coagulant therapy.\n* Severely impaired renal function; creatinine clearance \\\u003C30 mL\u002F min.\n* Subjects with significant liver dysfunction; Child Pugh classification C.\n* Known diagnosis of active or untreated hepatitis B, hepatitis C, tuberculosis.\n* Any other illness or medical condition that in the investigator's opinion precludes participation in this study.\n* Pregnant or lactating women.\n* Expected uncontrollable therapy non-compliance\u002F non-cooperation that is likely to interfere with the study procedure, as per judgement of the investigators.\n* Head circumference ≤ 49 cm.\n* Weight ≥ 135 kg.\n* Patient ≥ 18 years old, who requires general anesthesia to undergo the Exablate BBBO procedure.\n* Contra-indication for MRI procedures.\n* Known sensitivity to gadolinium-based contrast agents.\n* Known sensitivity to the resonator agent (perflutren; Luminity®).","4 Years",{"count":19,"type":20},[23,57],"This study is for people (children and adults) with a rare and aggressive brain tumor called H3K27-altered diffuse midline glioma (DMG) located in the pons, a deep part of the brainstem. These tumors are very difficult to treat because they grow into surrounding brain tissue and cannot be fully removed with surgery. Most patients currently survive less than one year after diagnosis, and treatment options are limited.\n\nCurrent standard treatment The usual treatment is radiotherapy, sometimes combined with a chemotherapy drug called temozolomide (TMZ). This combination may slightly improve outcomes, but it is often not very effective for tumors in the pons. One possible reason is that the blood-brain barrier (BBB)-a natural protective filter in the brain-may be especially strong in this area, making it harder for medicines to reach the tumor.\n\nWhat this study is testing This study is exploring a new approach to help chemotherapy reach the tumor more effectively. It uses MRI-guided focused ultrasound (with the Exablate system) to temporarily and safely open the blood-brain barrier in the tumor area. This may allow more temozolomide to enter the tumor.\n\nStudy goal\n\nThe main goal is to find out:\n\n* Whether this technique is safe\n* Whether it may help slow tumor growth or extend survival\n\nWho can join\n\n* Adults and children aged 4 years and older\n* Diagnosed with H3K27-altered pontine DMG\n* Eligible for temozolomide after completing radiation therapy\n\nThe study will include 20 participants (about half children and half adults).\n\nWhat participants will do\n\nParticipants will:\n\n* Receive 6 cycles of temozolomide chemotherapy\n* Undergo focused ultrasound blood-brain barrier opening on the first day of each cycle\n* Have regular MRI scans and check-ups to monitor safety and tumor response\n\nEach treatment cycle includes 5 days of chemotherapy followed by a rest period of 23 days.\n\nWhat the study is measuring\n\nResearchers will look at:\n\n* Safety of the procedure and device\n* How long patients live without tumor progression (progression-free survival)\n* Overall survival\n* Tumor response to treatment\n* Whether the procedure is practical to use in clinical care\n\nThey will also compare results to data from previous patients in international brain tumor registries.\n\nWhy this study matters This study is testing whether temporarily opening the brain's natural barrier can help chemotherapy work better in a type of brain tumor that currently has very limited treatment options.",[29],[94,95,96,97,98],"DMG","DIPG","Focused ultrasound","Exablate","Temozolomide","NOT_YET_RECRUITING","2026-04-28",{"date":69,"type":36},{"date":103,"type":20},"2026-05",{"date":105,"type":20},"2031-11",{"name":107,"class":43},"UMC Utrecht",2]